Although the here-evaluated KIR-ligand-mismatched subsets comprise a rather small percentage of total NK cells, KIR-ligand mismatching helps to reduce inhibition in these subsets, which can nonetheless be beneficial in a TME where many factors can limit NK cell anti-tumor responses. Here, KIR3DL1 is linked to neoplasm.